Automation and Information Management Impact at AbbVie
Accelerate Process Development and Product Quality
Automation and information management technologies are increasingly being used in the following ways:
- Development and manufacturing of therapeutics across the pharmaceutical industry
- To collect, analyze, and interpret an immense amount of advantageous process data, that would otherwise be inaccessible
This combination provides many additional benefits, such as:
- Enabling processes
- Ability to safely handle highly reactive, unstable and toxic reagents
All these aspects help to minimize the time and cost associated with the development and manufacturing of drugs, and bring medicines to patients more effectively. The importance of such concepts became even more evident during the COVID-19 pandemic. Different organizations are now actively thinking of implementing these paradigms to their benefit. This presentation shares AbbVie’s strategy and experiences in integrating automation technologies into process development and manufacturing facilities. The challenges and opportunities associated with the approaches are discussed.
Join the hundreds of researchers who already viewed this presentation.
About the Presenters
Moiz Diwan, Ph.D.
AbbVie Inc.
Moiz Diwan is a director within the Process Research and Development organization at AbbVie. Moiz has led early to late-stage pharmaceutical development teams involving drug substance control strategy development, establishing global supply chain, process tech-transfer and scale-up, and authored global regulatory filings for 1st Gen. HCV Viekira and HCV Next Gen. Mavyret drugs. Presently, Moiz is leading Center of Excellence for Enabling Technology Development, a cross functional team of chemists, engineers and PAT scientists impacting all small molecule projects.
Shashank Shekhar, Ph.D.
AbbVie Inc.
Shashank Shekhar is the Head of the Center of Catalysis at AbbVie. Shashank has developed several catalytic processes that have been applied across AbbVie’s pipeline compounds, including commercial products such as Vikera Pak, Mavyret and Imbruvica. He has also led process development of several candidates in Phase 1 to 3 clinical trials. He currently heads the discovery and development of organometallic, bio-catalytic and high-pressure catalytic reactions at AbbVie.
